Cerebral Prophylactic Irradiation With Saving Hippocampus and Amygdala

Savings of Hippocampus and Amygdala by Archetherapy in Cerebral Prophylactic Irradiation in Patients With Limited and / or Extended, Responsive or Stable Small Cell Lung Cancer (SCLC)

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03209128

Acronym

IPC

Enrollment

Registered

2017-07-06

Start date

2017-04-20

Completion date

2021-03-19

Last updated

2022-06-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non Small Cell Lung Cancer

Brief summary

Hippocampus and amygdala are parts of the brain involved in the recognition of emotions, memories, memory, language ... It is therefore very important to protect them during irradiation of the brain. The aim of this study is to evaluate cerebral irradiation with saving hippocampus and amygdala protects these brain functions in patients with small cell lung cancer (SCLC) Radiotherapy of the brain

Interventions

RADIATIONIrradiation prophyllactique cérébrale

Irradiation prophyllactique cérébrale

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients over 18 years of age * Patients with a limited SCLC demonstrated histologically responsive or stable to radiochemotherapy or patients with a histologically proven extended SCLC responding to chemotherapy. * WHO Performance Index 0-1 and / or Karnovsky Index\> 70 * Possibility of long-term monitoring

Exclusion criteria

* Concomitant chemotherapy * Impossibility of performing an MRI or CT without injection * Presence of cerebral metastases * History of cerebral irradiation at any time * Patient suffering from severe collagenosis * Patient with cognitive disorders with MMSE score \<24

Design outcomes

Primary

Measure	Time frame	Description
Cognitive function	until 18 months after inclusion of patient	Evaluate the cognitive function with Wechsler Memory Scale IV (WMS-IV) test

Secondary

Measure	Time frame	Description
Secondary effects according the CTCAE v.4 criteria	until 18 months after inclusion of patient	Evaluate the toxicity according the CTCAE v.4 criteria
Appearance of brain metastases and their location	until 18 months after inclusion of patient	Evaluate the brain control with brain MRI
Quality of life (QOL) of patients	until 18 months after inclusion of patient	Evaluate QOL with FACT-BR test (Functional Assessment of Cancer Therapy-Brain)

Countries

Luxembourg

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026